ASK8007 / Astellas - LARVOL DELTA

SPP1 as a predictive biomarker and therapeutic target in fibrotic (TTS 2026) - "Therapeutic targeting used ASK8007, an anti-SPP1 monoclonal antibody, delivered via hyaluronic acid-coated lipid nanoparticles in kidney transplant models... This study presents SPP1 as a central mediator of CAD progression, a clinically actionable predictive biomarker, and a promising therapeutic target for precision interventions in kidney transplantation. The findings challenge the conventional immune-centric paradigm, propose a dual epithelial–immune model of fibrosis, and introduce a novel therapeutic delivery strategy for targeted anti-SPP1 therapy."

Biomarker • Chronic Kidney Disease • Fibrosis • Immunology • Inflammatory Arthritis • Nephrology • Rheumatoid Arthritis • CST3 • SPP1

SPP1 as a Predictive Biomarker and Therapeutic Target for Chronic Renal Allograft Dysfunction (ATC 2026) - "This framework establishes SPP1 as central CAD mediator, actionable biomarker, and therapeutic target for precision interventions."

Biomarker • Fibrosis • Immunology • Nephrology • SPP1

Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them. (PubMed, Front Aging Neurosci) - "The drug-gene interaction analysis showed that four drugs (avacopan, CCX354, BMS-817399, and ASK-8007) could be potential drugs for VaD and carotid atherosclerotic plaques treatment. Collectively, these findings indicated that inflammatory and immune-related processes be a crucial common pathophysiological mechanism shared by VaD and carotid plaques. This study might provide new insights into common molecular mechanisms between VaD and carotid plaques and potential targets for the treatment."

Journal • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Dementia • Dyslipidemia • Immunology • CD4